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Abstract.  CD31  is a member of the immunoglobulin 
superfamily consisting of six Ig-related domains.  It is 
constitutively expressed by platelets, monocytes, and 
some lymphocytes, but at tenfold higher levels on vas- 
cular endothelial cells. CD31 has both homotypic and 
heterotypic adhesive properties.  We have mapped the 
homotypic binding sites using a deletion series of 
CD31-Fc chimeras and a panel of anti-CD31  monoclo- 
nal antibodies.  An extensive surface of CD31 is in- 
volved in homotypic binding with domains 2 and 3 
and domains 5 and 6 playing key roles. A  model con- 
sistent with the experimental data is that CD31  on one 
cell binds to CD31  on an apposing cell in an anti- 
parallel interdigitating  mode requiring full alignment 
of the six domains of each molecule. In addition to 
establishing intercellular homotypic contacts, CD31 
binding leads to augmented adhesion via/31  integrins. 
The positive cooperation between CD31 and 151 inte- 
grins can occur in heterologous primate cells (COS 
cells). The interaction is specific to both CD31 and E1 
integrins.  Neither intercellular adhesion molecule-1 
(ICAM-1)/leukocyte  function-associated antigen-1 
(LCAM-1)  nor neural cell adhesion molecule 
(NCAM)/NCAM adhesion leads to recruitment of E1 
integrin adhesion pathways. Establishment of CD31 
contacts have effects on the growth and morphology of 
endothelial cells.  CD31(D1-D6)Fc inhibits the growth 
of endothelial cells in culture.  In addition,  papain 
fragments of anti-CD31  antibodies (Fab fragments) 
disrupt interendothelial  contact formation and 
monolayer integrity when intercellular contacts are be- 
ing formed. The same reagents are without effect once 
these contacts have been established,  suggesting that 
CD31-CD31  interactions  are critically important only 
in the initial phases of intercellular adhesion. 
key function of endothelial cells lining the vasculature 
is their ability to sustain  an extensive  network of 
intercellular  adhesive  contacts to maintain  the in- 
tegrity of the circulatory system. A number of cell adhesion 
molecules contribute to this  function,  including  integrins 
and cadherins  (Lampugnani et al., 1991, 1992). Members of 
the immunoglobulin  superfamily, such as intercellular  adhe- 
sion  molecule-1  (ICAM-1)  ~ and  vascular  cell  adhesion 
molecule-1 (VCAM-1), play key roles in mediating the adhe- 
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sion of circulating  leukocytes to endothelial  cells (Bevilac- 
qua,  1993). The only report of the role of immunoglobulin 
superfamily (IgSF) members in maintaining interendothelial 
cell contacts,  comes from work on endoCAM, the bovine 
homologue of CD31 (Albelda et al., 1990). Polyclonal anti- 
endoCAM antibodies  disrupt bovine adrenal  capillary en- 
dothelial contacts.  Electron microscopy studies have shown 
that CD31 is present in interendothelial  contact areas, but it 
is absent from the very tight junction zones (Leach  et al., 
1993; Ayalon et al.,  1994). 
CD31  (also known as platelet  endothelial  cell adhesion 
molecule-1 [PECAM-1]) is a type I integral membrane pro- 
tein,  and  its  extraceUular  domain  consists  of six  Ig  C2- 
related  domains  (Newman  et al.,  1990;  Simmons  et al., 
1990;  Stockinger  et all., 1990).  Murine CD31 shares  the 
same domain organization,  and the amino acid similarity  is 
79% overall (Xie et al., 1993). CD31 is a constitutively and 
abundantly  expressed  surface glycoprotein  on vascular en- 
dothelium,  with up to 1 million molecules per cell (Newman 
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on platelets (5-8,000 per cell), monocytes, and neutrophils 
(100,000 per cell). Approximately 50% of T cells also ex- 
press CD31, but at much lower levels than on myeloid cells 
(Stockinger et al.,  1992;  Bird et al.,  1993). 
CD31 has both homo- and heterotypic adhesive properties 
(Albelda et al., 1991; Muller et al., 1992; DeLisser et al., 
1993, Watt et al., 1993). The heterotypic binding site is lo- 
cated in domain 2, which contains a consensus motif for the 
recognition of  heparan sulphate and has been recently shown 
to bind glycosaminoglycans via this domain. The domains 
mediating homotypic adhesion have not been identified. 
The high expression levels of CD31  on endothelial cells 
and its sequestration at sites of intercellular contact strongly 
suggest that it might play a role in the maintenance of the 
integrity of the vascular monolayer (Muller et al.,  1989; 
Schimmenti et al.,  1992).  In addition, the distribution of 
CD31  in the cell membrane changes as endothelial cells 
differentiate into capillary-like structures. Moreover, the cy- 
toplasmic tail of CD31 is phosphorylated de novo on serine 
and threonine residues as cells are activated, further pointing 
to a role in endothelial cell adhesion (Newman et al., 1992; 
Zehnder et al., 1992).  DeLisser et al. (1994) have recently 
demonstrated a direct role for the cytoplasmic tail in hetero- 
typic binding; deletions of the tail resulted in a change from 
predominantly heterotypic to homotypic binding. 
CD31  is also involved in apparently amplifying the inte- 
grin-mediated adhesion of CD8  + T cells to matrix compo- 
nents (Tanaka et al., 1992).  This novel mechanism, involv- 
ing "cross-talk" between CD31 and l~l, and to a lesser extent 
~2 integrins, requires that CD31 is merely dimerized in the 
cell membrane by single monoclonal antibodies. This effect 
has also been demonstrated for murine CD31  (Piali et al., 
1993).  In addition, CD31 may act as a signaling molecule 
in monocytes since coligation of CD31 with FcR'yII leads to 
induction of  proadhesive cytokines (TNF-ot, IL-1 ~, and IL-8) 
(Chen et al.,  1994). 
CD31 has been shown to play a role in the transendothelial 
migration  of monocytes and  neutrophils  (Muller  et  al., 
1993).  A monoclonal antibody to CD31  inhibited the ran- 
dom migration of monocytes and neutrophils across an en- 
dothelial monolayer, as did a  recombinant form of CD31 
consisting of domains 1-5 and a half of domain 6. However, 
the expression of CD31 on lymphocytes is not a prerequisite 
for transendothelial migration (Bird et al., 1993).  Two ani- 
mal model studies have shown that CD31  is important for 
neutrophil extravasation in vivo.  Firstly, rabbit polyclonal 
antibodies raised against human CD31 that cross-react with 
rat CD31 block accumulation of rat neutrophils into the peri- 
toneal  cavity and  the  alveolar  compartment of the  lung 
(Vaporciyan et al., 1993). In addition, this reagent inhibited 
neutrophil accumulation in human skin grafts in immuno- 
deficient mice. Secondly, in a murine model of acute perito- 
nitis, an antimurine CD31 mAb inhibited leukocyte and par- 
ticularly neutrophil emigration (Bogen et al.,  1994). 
To analyze directly the role of CD31 in mediating interen- 
dothelial cell interactions, we have generated soluble recom- 
binant forms of CD31 as fusion proteins with human IgG1Fc, 
and we have used these in a number of structural and func- 
tional studies. We confirm that CD31  can mediate homo- 
typic adhesion and extend these  studies by  showing that 
homotypic binding involves extensive interdigitation of ap- 
posed CD31  molecules and specific engagement of binding 
sites located in domains 2 and 3 and domains 5 and 6. Fur- 
thermore, we have demonstrated positive cooperative inter- 
action between CD31  and/31  integrin adhesion pathways in 
heterologous primate  cells.  Significantly, presentation  of 
CD31-Fc  to endothelial cells inhibits cell proliferation. In 
addition, both CD31-Fc and anti-CD31 polyclonal antibod- 
ies dramatically impair the ability of endothelial cells to es- 
tablish normal intercellular contacts and to form an integral 
monolayer, but they have no effect once monolayers have 
formed. 
Materials and Methods 
Cell Culture and Antibodies 
Human umbilical vein endothelial cells (HUVEC) were established from 
freshly  isolated  full-term umbilical cords  and cultured  using  standard 
methods Oaffe et al., 1973). The cell lines U937, H82, COS-l, and COS-7 
were obtained from the Imperial Cancer Research Fund (ICRF) ceil bank. 
MIKALL was a gift from Dr. Sue Watt (Medical Research Council, Molec- 
ular Haematology  Unit, Institute of Molecular Medicine, Oxford). All cells 
were grown in RPMI/10%  FCS or DME/10%  FCS. mAbs were as follows: 
anti-CD31  mAbs 9(311 and 10B8 both IgG1 (Simmons et al.,  1990;  and 
British Biotechnology,  Oxford,  UK); JC70A IgGl (Parums et al.,  1990); 
HC1/6 IgG1 (Serotec, Kidlington,  UK); 5.6E IgG1 (Immunotech, The Bind- 
ing Site, Birmingham, UK); L133.1 IgG1 (Becton Dickinson, Oxford, UK); 
WM59 IgG1 (TCS Biologicals,  Bucks, UK), CLB/CD31  IgGl (Monosan, 
Bucks, UK); anti-l~l integrin mAbs were clone 13 rat IgG2a (Becton Dick- 
inson) and clone 4134 IgGl (Coulter Clone, Bucks,  UK); anti-B3 integrin 
mAb was clone RUU-PL 7F12 IgG1 (Becton Dickinson); anti-LFA-1/CDI la 
integrin mAb MHM24 IgGl was a gift from Prof. Andrew McMichael (In- 
stitute of Molecular Medicine, Oxford).  Polyclonal rabbit anti-NCAM an- 
tiserum was a gift from Dr.  Patrick Doherty (Department of Pathology, 
United Medical and Dental Schools of Guys' and St. Thomas's Hospitals, 
London). 
Transient Expression 
and Immunofluorescence Staining 
Individual constructs (10-20/~g DNA) were introduced into 107 COS cells 
incubated for 4 h at 37°C with 400 ~g/ml DEAE-dextran and 100 ~M chlo- 
roquine  in serum-free DME  followed  by  a  2-rain hypotonic shock in 
PBS/10% DMSO (Simmons,  1993). For LFA-I expression,  COS cells were 
transfected with 50 ~g of both CDlla and CDI8.  After 48-72 h in culture, 
the transfected cells were incubated with mAbs for 20 rain at 4°C followed 
by staining with FITC-conjugated  goat anti-mouse IgG or IgM antibodies 
(Sigma Chemical  Co., Poole, Dorset, UK) as appropriate.  For cytofluoro- 
metric analysis, COS transfectants  were lifted 48-72 h after transfection  in 
PBSf2 mM EDTA, washed in PBS/0.2%  BSM0.02% azide at 4oc, stained 
with primary mAbs, washed three times, stained with a  1:200 dilution of 
FITC-conjugated  goat anti-mouse (Sigma),  washed  three times, fixed in 
PBS/2% glntaraldehyde,  and analyzed on a Becton Dickinson FACScan  °, 
For all assays involving transiently expressed adhesion molecules,  the per- 
centage of positive cells was defined by positioning  the marker gate such 
that >2% of the negative  control population were deemed positive.  All 
adhesion assays using COS transfectants  were normalized with respect to 
the percentage of COS cells expressing  specific constructs. 
Construction of CD31 Deletion Plasmids 
A full-length CD31 eDNA clone (CD3 I(DI-D6) transmembrane [TM]) iso- 
lated by transient expression screens of HUVEC cDNA libraries was used 
as a template for all polymerase chain reaction constructs (Simmons et al., 
1990). The PCR strategy  for construction of soluble forms was as follows. 
PCR conditions:  four cycles of 940C,  1 min; 45°C,  2 rain; 72°C,  2 rain; 
followed by 30 cycles of 94°C, 30 s; 45°C, 30 s; 72°C,  1.5 rain. The primers 
used were: pCDM8 forward amplification primer plus reverse amplification 
primers containing the common adaptor sequence 5' GATCAGATCTACT- 
TACCTGT plus domain specific sequences as follows: domain 1, CAC CCT 
GGG ACT GGG CAC TCC; domain 2, AGA GAA GGA TIC CGT CAC 
GGT; domain 3, GAA GGA AGA TTC CAG ~  ~;  domain 4, AAT 
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CGG GGC; domain 6, TTT CTT CCA TCd3 C_fJC AAG AAT 3'. PCR prod- 
ucts were cut with HindflI and BglII and cloned into the pig vector (Fawcett 
et ai.,  1992;  Simmons, 1993) cut with HindIII plus BamHI. 
Neural cell adhesion molecule (NCAM) was isolated by transient expres- 
sion/panning of a fetal brain cDNA library. CDIla was a gift of Dr. Clive 
Landis (Leukocyte Adhesion Laboratory, ICRF). CDI8 was isolated by hy- 
bridization screening from a U937 cDNA library. Negative control chimeric 
Fc proteins were CD33(DI-D2)Fc (Simmons, 1993),  MUCI8-Fc (Fawcett 
et al., 1992),  and ICAM-I(D1-D5)Fc, a giR from Dr. Alastair Craig (Insti- 
tute of Molecular Medicine, Oxford, UK). All constructions were checked 
by restriction digests and DNA sequencing. 
Generation of Chimeric Fusion Proteins 
and Immunoprecipitations 
CD31-Fc fusion plasmids were transfected into COS cells (10/zg/107 COS 
cells) using DEAE-dextran as a facilitator (Simmons, 1993).  The medium 
was changed at 24 h to DME/0.5% FCS, and the supernatants were har- 
vested at 7 d. Fusion proteins were affinity isolated on protein A-Sepharose 
(Pharmacia, Milton Keynes, UK); columns were washed with 0.1 M gly- 
cine, pH 5.0 (to remove bovine IgG), and Fc chimeras were eluted with 
0.1 M  glycine, pH 3.0, neutralized immediately in 10%  vol/vol 1 M Tris 
base, buffer exchanged, and concentrated by centrifugal dialysis (Centricon 
10 U; Amicon, Beverly,  MA).  For production of labeled proteins, COS 
transfectants were grown in methionine-free medium containing 5% dia- 
lyzed  FCS  and  50  /~Ci/ml  [35S]methionine/cysteine  (Translabei;  ICN, 
Bucks, UK) for 18 h. Supernatants were harvested, and labeled secreted 
proteins were isolated by affinity purification with protein A-Sepharose. 
Bound proteins were eluted by boiling in Laemmli sample buffer under 
reducing conditions and resolved on 10% SDS-PAGE. Gels were fixed, im- 
pregnated with Amplify (Amersham, Bucks, UK), dried, and exposed to 
x-ray film for 12 h at  -80°C. 
Generation of  Anti-CD31 Polyclonal Antiserum 
Young  adult New Zealand white rabbits were injected three times sub- 
cutaneously with 100/tg of CD31(D1-D6)Fc  recombinant protein, once in 
complete and twice in incomplete Freund's adjuvant, during a course of 8 
wk. The preimmune serum and serum from immunized rabbits were tested 
in an ELISA to determine specificity of binding to HUVEC. Results (not 
shown) revealed that there was significant binding to HUVEC in the im- 
mune serum at 1/100,000 dilution, whereas binding of the preimmune sera 
was negligible at 1/10,000. All subsequent bleeds were tested for activity 
against HUVEC using ELISA. The specificity of the sera were checked by 
FACscan  ~  analysis of CD31(DI-D6)TM+COS  and  immunoprecipitation 
from t25I surface-labeled HUVEC. HUVEC were labeled using 125I and 
lactoperoxidase as Enzymobeads (Bio Rad Laboratories, Richmond, CA) 
according to the vendor's instructions. In this study,  sera were used from 
two different rabbits, and similar results were seen with both. 
Isolation of  lgG and Preparation of  Fab Fragments 
Final anti-CD31 sera were pooled, and IgG was affinity isolated on protein 
A-Sepharose. The IgG was desalted on PD10 columns (Pbarmacia) and 
concentrated  by centrifugal dialysis (Centricon 10; Amicon). Fab fragments 
were  generated  using  immobilized  papain  (Pierce  Europe  b.v.,  oud- 
Beijerland, Holland) according to the manufacturer's instructions. Fab frag- 
ments were dialyzed against PBS or RPMI  1640  overnight. Successful 
generation of fragments was confirmed using SDS-PAGE. In most cases, 
Fab fragments were used at 50-100 ~g/ml. 
Electron Microscopy 
Because of the opacity of the polycarbonate membranes in the Transwell 
cell culture inserts (Costar UK, High Wycombe, Bucks,  UK), HUVEC 
grown in the presence of anti-CD31 or preimmune Fab fragments were ob- 
served by electron microscopy. HUVEC were washed twice in serum-free 
RPMI 1640 and fixed in 2.5%  glutaraldehyde in PBS. The base of each 
Transwell was carefully cut out,  and the samples were dehydrated and 
processed into Epon Resin. "Gold  ~ (90--120 nm) sections were cut, mounted 
on copper grids, stained with uranyl acetate and lead citrate, and examined 
in a Philips 200 electron microscope. Filters were flat embedded and cut 
so that cross-sections of endothelial cells on the filter were obtained. 
Adhesion Assays 
COS cells were labeled for 24-48 h with [3H]thymidine (Amersham) (10 
~tCi/2  x  107 cells). Transfection efficiency was checked by cytofluorogra- 
phy and was usually  15-30%.  Cells were lifted with PBS/2 mM EDTA, 
washed three times in RPMI-1640, and resuspended in assay buffer (RPMI 
1640 20 mM Hepes/0.2% BSA) at 3-4  x  104 cells/well. When the effect 
of  antibodies was being tested, mAhs or Fab fragments at 10-50 ttg/nfi were 
added to the cell suspensions at room temperature for 10 min before the as- 
say and included during the assay, unless otherwise stated. When the effect 
of CD31Fc fusion proteins as direct competitors was being tested, proteins 
at 250 ~tg/ml were added to COS CD31(D1-D6)TM  transfectants at room 
temperature for 10 rain before the assay, and they were included during the 
assay. 
For adhesion assays with cell lines (U937,  H82, and MIKALL), cells 
were labeled for 48 h with [3H]thymidine at 10/~Ci/107  cells. Cells were 
washed three times in assay buffer and 2 x 103 cells added per well in 96- 
well plates. Assays were performed in the absence and presence of heparin 
at 100/~g/ml to block heterotypic adhesion. 
96-well adhesion assay plates (Immulon 3; Dynatech Research Laborato- 
ries, Chantilly, VA) were prepared by precoating wells with 1 ;tg/well of 
affinity-purified goat anti-human Fc antibody (Sigma) overnight at 4°C. 
Plates were washed three times in PBS, and remaining unbound sites were 
blocked with PBS/0.4 % BSA (Fraction V; Sigma) for >~2 h at room tempera- 
ture. 50 ~tl of recombinant proteins at 10/~g/ml were then bound, and plates 
were washed three more times in PBS. 
FOr LFA-I assays, LFA-I+COS cells were stimulated with PMA (Sigma) 
by incubating cells in 50 ng/ml (80 nM), PMA for 30 rain at 37°C and the 
PMA was removed by washing in assay buffer. 
Cells were allowed to adhere for 60 min (or ~3 h in some assays) in assay 
buffer at 37°C. At the conclusion of the incubations, the wells were washed 
two times with prewarmed assay buffer using a continuous flow of assay 
buffer at a head of pressure of 30 cm of water using a siphon arrangement. 
Between washes, the wells were emptied by inversion. Cells that remained 
bound after two washes were lysed in 1% SDS, scintiliant was added (Ready 
Safe; Beckman, High Wycombe, UK), and incorporated radioactivity was 
counted using a Beckman LS 5000 CE counter. 
All adhesion assays were performed on at least three independent occa- 
sions, and representative  experiments are shown. Each data point represents 
the mean of six replicates. 
ELISA of CD31-Fc Proteins 
Immulon-3, 96-well ELISA plates, were prepared as adhesion plates. Plates 
were precoated with 1 tzg/well goat anti-human-Fc Ig (Sigma) overnight at 
4°C, blocked with PBS/2% BSA (Fraction V; Sigma) for 2 h at room tem- 
perature, and then coated with chimeric proteins (5 #g/ml) in PBS for ~2 h 
at room temperature. Antibodies were added at 10/~g/mi or as neat tissue 
culture supernatants, followed by horseradish peroxidase-conjngated goat 
anti-mouse Ig (1:1,000 dilution; Amersham). Each layer was incubated for 
60 rain at room temperature and followed by six washes with PBS/0.2 % 
BSA/0.02%  azide. The assay was visualized with O-phenylenediamine di- 
hydrochloride (Sigma), and absorbance was read at 450 rim. 
Growth of  HUVEC in the Presence of  Fc Chimeras 
A pilot experiment was undertaken to determine the dose response of chi- 
meric Fc proteins on the growth of HUVEC. 24-well Primeria (Falcon, Bec- 
ton Dickinson, Oxford,  UK) dishes were coated with fibronectin at  10 
~tg/ml and varying concentrations of CD31(D1-D6)Fc  or CD33(DI-D2)Fc 
(CD33 is a myeloid surface protein with no known iigand on endothelial 
cells and was chosen as a negative control for IgSF-Fc chimeras; Simmons 
and Seed, 1988).  For all these experiments, early passage HUVEC (p2 or 
p3) were used. Cells were seeded at a subconfluent initial density of 104 
cells/well. The medium in each well was changed daily, and at 5 d, the total 
number of cells was counted in each well. Duplicate wells for each concen- 
tration of Fc protein coating were set up, and the results are shown as the 
mean number of cells in duplicate wells. In control wells, there was an ap- 
proximate six- to sevenfold increase in total cell numbers during the course 
of the experiment. 
The dose response analysis indicated that CD3 I(DI*D6)Fc  was effective 
at 50 ~g/ml, so this coating concentration was used for the second set of 
experiments involving a time course of growth over a period of 7 d in the 
presence of fibronectin (FN)  alone,  FN  +  CD31(DI-D6)Fc,  or FN  + 
CD33(DI-D2)Fc. For the time course experiment, HUVEC were seeded at 
5  x  103 per well in Falcon Primeria 24-well cluster plates coated with 
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Figure 1. Characterization of CD3 l-Fc chimeric proteins. (a) Dia- 
grammatic representation  of full-length  membrane expressed CD31 
(CD31(D1-D6)TM)  and  deletion  series  of  CD31Fc  chimeras: 
CD31(D1)Fc,  CD31(D1-D2)Fc,  CD31(D1-D3)Fc,  CD31(D1-D4)Fc, 
CD31(D1-D5)Fc,  and CD31(D1-D6)Fc.  (b) SDS-PAGE analysis of 
CD31-Fc  domain deletion  series.  Lane  1,  CD31(D1)Fc;  lane 2, 
CD31(D1-D2)Fc;  lane  3,  CD31(D1-D3)Fc;  lane  4,  CD31(D1- 
D4)Fc;  lane 5,  CD31(D1-D5)Fc;  lane 6,  CD31(D1-D6)Fc;  lane 7, 
molecular  weight  markers.  35S-labeled  CD31-Fc  proteins  were 
affinity isolated on protein A-Sepharose, eluted with Laemmli sam- 
ple buffer, and resolved on 10% SDS-PAGE. Molecular masses are 
indicated in kilodaltons. 
fibronectin  at 10 #g/ml alone or in combination with either CD3 I(D1-D6)Fc 
or CD33(D1-D2)Fc at 100 #g/nil. Cells were fed daily with DME/10% FCS 
supplemented with basic FGF at 10 ng/ml. Cell numbers were measured 
by counting, and results are expressed as the mean number -1-  1 SD (n  =  4). 
HUVEC Culture on TransweU Cell Culture Inserts 
and Monolayer Integrity Testing 
105 HUVEC were seeded in the presence of preimmune or CD31 antisera 
or Fab fragments into Transwell tissue culture inserts (diameter =  6.5 ram) 
containing 3.0-#m pore polyearbonate membrane bases (Costar UK) that 
had been fibronectin coated (50 #g/ml; Sigma).  Cells were then left over- 
night to form a monolayer. In some experiments,  HUVEC were seeded in 
the absence of antisera or Fab fragments.  Dilutions of antisera used were 
in the range 1/50-1/500. Fab fragments were used at 50-100 #g/ml. 
The next day, the integrity of the monolayers  was assessed  using [14C]- 
mannitol, as described in Bird et al.  (1993).  Briefly, 4.4  x  104 dpm of 
[14C]mannitol (Amersham) was added to each well insert. After incuba- 
tion at 370C for 30 rain, proportionally equal samples of tissue culture me- 
dia were removed from the insert and the well, and were counted on a liquid 
scintillation counter. The counts from the well were expressed as a percent- 
age of those remaining in the insert. The results from inserts incubated with 
preimmune or CD31  antisera or Fab fragments were compared for differ- 
ences in percentage equilibration values (counts in well)/(counts  in insert) 
x  100. In some experiments,  HUVEC monolayers that had been set up on 
filters alone were tested and then incubated with preimmune or immune an- 
tisera or Fab fragments, and were then retested at a later time. Experiments 
were performed on at least three independent occasions  with no less than 
four replicates  in each experiment. 
Results 
Mapping the Homotypic Binding Sites in CD31 
Molecular  Tools. To map the homotypic binding site  in 
CD31, a series of truncated forms of CD31 consisting of the 
NH2-terminal  1,  1-2,  1-3, 1-4,  1-5, and 1-6 IgC2 domains 
of CD31 fused to the Fc region of human IgG1 were made: 
CD31(D1)Fc, CD31(D1-2)Fc, CD31(D1-3)Fc, CD31(D1-4)Fc, 
CD31(D1-5)Fc, and CD31(D1-6)Fc (Fig. 1 a). The chimeric 
genes were constructed by PCR amplification of CD31  to 
generate a 3' consensus splice donor sequence and restriction 
site; the PCR product was ligated into a vector pIgl, consist- 
ing of pCDM8 containing the genomic DNA sequences en- 
coding the hinge, CH2 and CH3 exons, and associated in- 
tronic sequences of human IgG1 3' to the cytomegalovirus 
promoter/enhancer sequences. When the chimeras were ex- 
pressed in metabolically labeled COS-1 cells, the affinity- 
isolated proteins all ran at the predicted sizes (Fig. 1 b). The 
conformationai integrity of the deletion chimeras was as- 
sessed by solid-phase ELISA using a  panel of eight anti- 
CD31  mAbs  (Table  I).  This  also  allowed assignment of 
mAbs to individual domains, mAbs 9Gll and JC70A recog- 
nize all six proteins and thus map to domain 1; mAbs L133.1, 
CLB/CD31, WM59, and 5.6E map to domain 2; mAb HC1/6 
maps to domains 4  and 5  so it could recognize an inter- 
Table L ELISA Profiles of Eight Anti-CD31 mAbs 
CD31 FC protein 
MUC18 
Antibody  D 1  D I-D2  D l-D3  D 1  ~IM  D l-D5  D 1  -D6  control 
9(311  0.235  0,276  0.292  0.291  0,292  0,292  0.050 
JC70A  0.29  0,317  0.311  0.317  0.283  0.297  0,052 
L133.1  0,054  0.187  0,208  0,207  0.246  0.224  0.049 
WM59  0.062  0.233  0.233  0.268  0.306  0.300  0,070 
CLB/CD31  0.059  0.230  0.242  0.237  0.293  0,249  0.051 
5.6E  0.063  0.204  0.224  0.184  0.229  0.207  0.050 
HCI/6  0.066  0.069  0,071  0.140  0,243  0.254  0.060 
10138  0.071  0.056  0.074  0.088  0.260  0.272  0.060 
Chimeric CD31-Fc proteins were immobilized via goat anti-human IgGlFc and screened with anti-CD31 mAbs. MUC18-Fc was included as a negative control 
IgSF-Fe chimera. Results are means of duplicates and are representative of two separate experiments. 
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Homotypic Adhesion. The standard assay used to analyze 
CD31  homotypic adhesion throughout this  study involved 
the binding of COS cells transiently expressing full-length 
CD31 or CD31 truncation mutants, to immobilized CD31- 
Fc chimeric proteins. This allowed us to dissect the roles of 
heterotypic versus homotypic adhesion, and it also allowed 
for the  normalization of the  amount  of chimeric protein 
presented to the input cells.  Surfaces coated with the full- 
length CD31(D1-D6)Fc chimera supported the adhesion of 
CD31(D1-D6)TM+COS  transfectants,  but not  sham  trans- 
fectants (Fig. 2 a). To demonstrate that this system was not 
an artefact of CD31 expressed in COS cells, adhesion assays 
were performed with CD31 ÷ cell lines, U937 and MIKALL. 
Both these cell lines bound to immobilized CD31(D1-D6)Fc 
(Fig. 2, a and c), but a small cell lung carcinoma line, H82, 
which is CD31  negative, did not (Fig. 2 a). 
Mapping Using Deletion Mutants.  To define the domain 
or domains responsible for mediating homotypic binding, 
COS cells expressing full-length CD31 were allowed to ad- 
here to surfaces coated with the series of CD31-Fc proteins 
(Fig. 2 b). The results show that the presence of domain 6 
was necessary to support significant homotypic adhesion, 
though CD31(D1-D5)Fc allowed partial adhesion (50%  of 
"full-length  " CD31(D1-D6)Fc adhesion). No other CD31-Fc 
chimera was able to bind CD31(D1-D6)TM+COS transfec- 
tants. The deletion series adhesion assay was repeated on a 
CD31 + lymphoid cell line, MIKALL, with similar results 
(Fig. 2 c); only CD3 I(D1-D6)Fc supported significant homo- 
typic adhesion. To rule out the potential of  heterotypic inter- 
actions via domain 2, both the CD31(D1-D6)TM+COS and 
MIKALL assays were repeated in the presence of 100 #g/ml 
heparin.  This concentration of heparin has been shown to 
block the heterotypic binding of domain 2 to heparan sul- 
phate-decorated proteoglycans. In the presence of heparin, 
the adhesion profiles were unaffected (data not shown). More- 
over, mock-transfected COS cells do not bind to CD3 I(D1- 
D6)Fc (Fig. 2 a). 
Although domain 6  is a  necessary component of CD31 
homotypic interactions, these experiments did not indicate 
whether domain 6 alone was sufficient to support adhesion. 
Alternatively,  binding  might  require  several  individually 
weak adhesion points, which amounted overall to measur- 
able adhesion in this assay system. 
Mapping by Adhesion Blockade 
Blocking with Domain-specific mAbs. To further define the 
binding  site,  the  panel  of  eight  anti-CD31  mAbs  was 
screened for their ability to block adhesion. Two of the four 
mAbs (L133.1 and 5.6E) that map to domain 2 block binding 
of CD31(D1-D6)÷COS  to CD31(D1-D6)Fc (Fig. 3 a). None 
of the other mAbs blocked in this assay. In fact, since all the 
mAbs were used as whole antibodies, there was an actual in- 
crease in  adhesion probably because of cross-bridging of 
CD31  on the COS cells to CD31  on the assay surface. 
The blocking assay was repeated on a  CD31 ÷ lymphoid 
cell line MIKALL with similar results; again, the only two 
blocking mAbs were 5.6E and L133.1  (data not shown). 
Blocking  with CD31Fc Fusion Proteins. The series of 
CD31-Fc fusion proteins was used as direct competitive in- 
Figure 2. CD31+COS/CD31-Fc homotypic adhesion assays; map- 
ping the binding site. (a) Adhesion of COS cells transfected with 
CD31(D1-D6)TM, sham (pCDMS)-transfected COS cells, U937 
(promonocytic, CD31+), and  H82  (small cell  lung  carcinoma, 
CD31-) to CD31(D1-D6)Fc immoblized on plastic. Assays are ex- 
pressed as mean percentage of total  input cells binding  -/-1 SD 
(n =  6). (b) Adhesion of CD31(D1-D6)TM+COS transfectants to 
plastic  coated  with  COOH-terminal  domain  deletion  series  of 
CD31-Fc proteins. The series used was CD31(D1)Fc, CD31(DI- 
D2)Fc,  CD31(D1-D3)F,c, CD31(D1-4)Fe, CD31(D1-D5)Fc, and 
CD31(DI-D6)Fc. Adhesion to a control protein, MUC18-Fc, is in- 
cluded as a negative IgSF-Fc control. Results are expressed as the 
means of the percentage of CD31(D1-D6)TM+COS cells binding 
+1 SD (n = 6), i.e., corrected for transfection efficiency.  (c) Adhe- 
sion profile of MIKALL to CD31 deletion chimeras. Results are 
expressed as the means of  the percentage of total input cells binding 
+1  SD (n  =  6).  All assays are normalized with respect to the 
perecentage of transfection efficiency. 
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ade. (a) mAb blocking. Screen of eight anti-CD31 mAbs for block- 
ade  of adhesion of CD31(D1-D6)TM+COS  to  CD31(D1-D6)Fc. 
Cells were incubated with mAbs at 10 ttg/ml for 10 rain at room 
temperature before the assay, mAbs were present during the assay, 
MUCI8-Fc is a negative control. The background level of binding 
in this assay is indicated by adhesion of CD3 I(DI-D6)TM+COS 
to  MUCIS-Fc.  (b)  CD31Fc  proteins  as  competitive inhibitors. 
CD31(DI-D6)TM  COS  cells  were  incubated  with  the  CD31Fc 
chimeras at 250/zg/rnl for 10 rain at room temperature before the 
assay. Cells were allowed to adhere for 1 h to CD31(D1-D6)Fc  im- 
mobilized on plastic. Chimeras were present during the assay. Two 
negative control competitors (MUCI8-Fc and  NCAM-Fc) were 
also used. The background level of binding in this assay is indicated 
by adhesion of CD31(DI-D6)TM+COS to MUC18-Fc. 
Figure 4.  Cross-talk between CD31 and/31  integrin adhesion. (a) 
Time course of adhesion of CD31(DI-D6)TM+COS to CD31(D1- 
D6)Fc and effects  of/~1  integrin-blocking mAbs.  The x  axis is 
total time in minutes.  -4,-, /32 MHM23;  -~-, no antibody; --u-, 
/~1  4]34; -4-,  /~1  13;  -u-,  MUCI8-Fc.  (b)  Effect of anti-CD31 
blocking  mAbs  (L133.1 and  5.6E)  added  at  various  times  on 
CD31-CD31 adhesion and/~1 integrin adhesion. Anti-CD31 mAbs 
were added at 30, 60, and 100 rain at a final concentration of 10 
#g/ml, and the assay continued for a total of 2 h, when all sample 
wells were washed and bound cells were counted. The "no anti- 
body" data set is the maximal level of adhesion at 2 h with no mAbs 
added,  m,  D2 blocker L133.1; m,  D2 blocker 5.6E;  @, D1  non- 
blocker 9Gll. 
hibitors  of  the  binding  of  CD31(D1-D6)+COS  to  CD31- 
(D1-D6)Fc immobilized on plastic. Neither CD31(D1)Fc nor 
CD31(D1-D2)Fc were effective competitors. However, CD31- 
(DI-D3)Fc reduced binding by 50%.  No further inhibition 
was seen with CD31(DI-IM)Fc, but a significant reduction in 
binding was seen with CD31(D1-D5)Fc and CD31(D1-D6)Fc. 
Thus, a combination of direct adhesion assays with CD31 
deletion  mutants  and  blocking  assays  with  mAbs  and 
The Journal of Cell Biology,  Volume 128, 1995  1234 (c) Lack of involvement of/~3 integrins in homotypic CD31 adhesion. CD31(D1-D6)TM+COS cells were allowed to adhere for 2 h to 
CD3 I(D1-D6)Fc in the absence or presence of/5'1,/32, or 83 integrin-blocking mAbs. CD3 I(D1-D6)TM+COS cells bind minimally to 
M  UC18-Fc. (d) Lack of involvement of/31 integrins in heterotypic LFA-1/ICAM-1 adhesion. LFA-I  +COS cells, activated with PMA, were 
allowed to adhere for 2 h to ICAM-I(DI-D5)Fc in the absence or presence of E1 or/~2 integrin-blocking mAbs. PMA-activated LFA- 
I*COS cells bind minimally to MUC18-Fc. (e) Lack of involvement of/31 integrins in homotypic NCAM-NCAM adhesion. NCAM+COS 
were allowed to adhere for 2 h to NCAM-Fc in the absence or presence of fll or/72 integrin-blocking mAbs. NCAM+COS cells bind 
minimally to MUC18-Fc. 
CD31Fc fusion proteins reveal that a very extensive surface 
of CD31 is involved in mediating homotypic adhesion. Mul- 
tiple domains play a part in the binding with key sites in do- 
mains 2 and 3, as well as domains 5 and 6. 
"Cross-talk" between CD31 and [31 Integrins 
There have been two reports describing an interaction or 
"cross-talk" between CD31 and 81 integrins (Tanaka et al., 
1992; Piali et al,, 1993). For both CD8  ÷ T cells and natural 
killer cells, cross-linking CD31 by single mAbs leads to in- 
creased adhesion mediated by 81  integrins. In preliminary 
experiments with the COS/CD31-Fc assay system, after the 
initial CD31-CD31 contacts had been formed during 30-60 
min, we observed a steady increase in cell binding over the 
course of the next 2-3 h. To investigate the possible involve- 
ment  of integrin  adhesion,  we  used  two  anti-/5'l integrin 
mAbs (mAbs 13 and 41M) known to block 81 integrin-medi- 
ated  adhesion.  These  mAbs  cross-react with  primate  /31 
integrin on COS cells; 95% of COS cells were positive for 
B1 integrin by cytofluorometry  (data not shown). Both mAbs 
reduced the overall adhesion by 50-70% (Fig. 4 a). A control 
82  integrin blocking mAb had no effect on the course of 
adhesion.  Background  binding  of CD31(D1-D6)TM+COS 
to  MUC18-Fc,  a  control  IgSF-Fc  chimera,  was  minimal 
(10% of CD31(D1-D6)Fc binding) and constant throughout 
the entire assay period, showing that COS cells do not intrin- 
sically bind to the assay surface during the period of the ex- 
periment. 
There was  a  continuing need for primary CD31-CD31 
homotypic contacts ~<60 min into the assay for the/5'1 inte- 
grin pathway to be active. If these contacts were blocked 
with either of the CD31 domain 2-blocking mAbs (5.6E and 
L133.1) at 30 or 60 min into a homotypic assay,  there was 
no significant adhesion (Fig.  4  b).  However, if the mAbs 
were  added  at  90  min  into  the  assay,  then  a  significant 
amount of CD31  independent adhesion remained. 
These results strongly suggest that the establishment of 
initial CD31-CD31 contacts leads to the upregulation or en- 
hancement of/31 integrin-mediated pathways of cell adhe- 
sion after an initial lag period of 60 min. The recruitment 
of integrin adhesion is  specific for the 81  class;  an mAb 
known to block 83 integrin adhesion (RUU-PL 7F12) had no 
effect  on the CD31-recruited adhesion (Fig, 4 c), even though 
COS  cells  express  high  levels  of 83  integrins  (data  not 
shown). 
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be specific to these molecules. Other IgSF adhesion mole- 
cules and other integrins do not postively interact to produce 
increased  adhesion.  Two  different  receptor  ligand  pairs 
(ICAM-I/LFA-1  and NCAM/NCAM) were used to see if the 
establishment of other primary contacts between the COS 
cells and the chimeric protein on the assay surface led to 
recruitment of/~1 integrin adhesion (Fig. 4, d and e). COS 
cells transiently expressing CD1 la/CD18 were activated with 
phorbol esters and were allowed to adhere to ICAMA(D1- 
D5)Fc.  The adhesion was blocked by the anti-B2 integrin 
mAb MHM23,  but not by either of the/31  integrin mAbs 
(Fig. 4 d). Similarly, COS cells expressing NCAM bound to 
NCAM-Fc in a homotypic manner that did not lead to in- 
volvement of/31 integrin adhesion (Fig. 4 e). In both of these 
cases, there axe comparable or even larger numbers of pri- 
mary contacts formed between the COS transfectants and the 
immobilized chimera on the plate, and yet there is no recruit- 
ment of/31 integrin adhesion to the system. 
CD31(D1-D6)Fc Inhibits the Growth 
of  Endothelial Cells 
Having  established  that  CD31(DI-D6)Fc  was  capable  of 
mediating homotypic adhesion, the functional effects of this 
reagent on endothelial cells were investigated. A  pilot ex- 
periment was undertaken to determine whether CD31(D1- 
D6)Fc coated onto plastic together with the normal substrate 
(fibronectin) would  affect the  growth  rate  of endothelial 
cells. Early passage HUVEC (p2 or p3) were seeded at sub- 
confluent densities in the presence of a range of concentra- 
tions of CD31(D1-D6)Fc (0.1,  1.0, 10, and 100 #g/ml) or a 
control  IgSF  member  CD33(D1-D2)Fc  (Fig.  5  a).  Cell 
proliferation was quantitated over a period of 5 d. CD33(D1- 
D2)-Fc had no inhibitory effect; HUVEC numbers increased 
sixfold over 5 d. However, CD3 I(D1-D6)Fc caused significant 
inhibition of endothelial cell growth at 50 #g/ml; HUVEC 
numbers increased only two- to threefold (Fig. 5 a). 
On the basis of this dose response study, a time course ex- 
periment was undertaken using a concentration of 50/~g/ml 
of chimeric protein together with fibronectin at 10 #g/ml. 
During a course of 8 d, the proliferation of HUVECs in wells 
coated with  the  CD31(D1-D6)Fc  was  retarded  compared 
with CD33(D1-D2)Fc-coated wells (Fig. 5 b). 
In both cases, CD31(D1-D6)Fc retarded the proliferation 
of HUVEC, but did not completely prevent it or lead to a de- 
crease in cell numbers compared to the initial input. These 
data suggest that CD31(D1-D6)Fc is cytostatic and not cyto- 
toxic. 
Generation of  Anti-CD31 Blocking Reagent 
To further explore the functional role of CD31 in intercellu- 
lar adhesion, polyclonal CD31 antisera were raised in rab- 
bits using CD3 I(D1-D6)Fc as an immunogen. The specificity 
of these reagents were established in two ways. Firstly, the 
affinity-purified IgG  fraction from these  sera  specifically 
recognized CD31(D1-D6)TM+COS transfectants (Fig. 6 a), 
and secondly, they precipitated a single 130-kD protein from 
~5I surface-labeled endothelial cells (Fig. 6 b). 
The  effect of the  polyclonal  anti-CD31  antisera  were 
tested to determine whether it blocked homotypic binding of 
CD31.  To avoid the confounding effects of cross-bridging 
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Figure 5. CD31(D1-D6)Fc inhibits the growth of endothelial cells. 
(a) Dose response of CD31(D1-D6)Fe. HUVEC were seeded at a 
subconfluent density on surfaces precoated with CD31(DI-D6)Fc 
or CD33(DI-D2)Fc over a range of concentrations. Cells were 
seeded on day 0 at 2  ×  104 cells/well. Total cell numbers were 
counted on day 5. Results are presented as means of  duplicate wells. 
-~-, CD31(D1-D6)Fc; -~, CD33(DI-D2)Fc. (b) Growth rates of 
HUVEC on surfaces coated with fibroneetin alone, or fibronectin 
plus 100 #g/ml of CD33(DI-D2)Fc or CD31(D1-Dt)Fc. Cells were 
seeded on day 0 at 5 ×  103 cells/well, and cell numbers measured 
by counting. Results are expressed as mean +1 SD (n =  4). -~-, 
CD31(DI-D6)Fc; -~, CD33(DI-D2)Fc; --n-, fibronectin. 
of CD31(D1-D6)TM molecules expressed on the COS cells 
to CD31(D1-D6)Fc bound to the plate, Fab fragments were 
prepared.  Preincubation of CD31+COS  transfectants with 
50/zg/ml Fab fragments of the anti-CD31 antibodies resulted 
in reduction of CD31-CD31 adhesion to background levels 
(Fig. 6 c). Thus anti-CD31 Fab fragments can block homo- 
typic CD31-CD31  adhesion. 
CD31 Antisera and Anti-CD31 Fab Fragments Disrupt 
Endothelial Monolayer Integrity 
The role of CD31  in the formation and maintenance of in- 
terendothelial contacts was assessed in two ways. 
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Figure 6. Anti-CD31 Fabs block homotypic adhesion.  (a) Characterization  of polyclonal anti-CD31 antibodies by FACScan  ® analysis of 
CD31(D1-D6)TM+COS and CD50 (ICAM-3)-transfected COS using IgG fraction from pooled serum at 1:1,000 dilution.  Control back- 
ground staining of  preimmune rabbit IgG is shown in each panel. (b) Characterization of  polyclonal anti-CD31 antibodies by immunoprecip- 
itation from surface l~I-labeled  HUVEC.  Lane 1, polyclonal anti-CD31 whole serum;  lane 2, polyclonal anti-CD31 IgG fraction;  lane 
3, anti-CD31 mAb 9Gll; lane 4, prebleed  serum;  lane 5, prebleed IgGl; lane 6, anti-ICAM-3  (CD50) mAb CH3.3. Molecular masses 
are indicated to the left in kilodaltons.  (c) Anti-CD31  Fabs block homotypic adhesion.  Adhesion of CD31(D1-D6)TM+COS or mock- 
transfected COS to CD3 I(D1-D6)Fc immobilized on plastic in the absence or presence of anti-CD31 polyclonal antibodies (whole antibody 
or Fabs).  All antibodies were present  throughout  the adhesion  assay and used at 50/~g/ml.  Results are expressed as means  +  1 SD 
(n  =  8).  I, CD31(D1-D6) COS; ~, sham COS. 
The first quantitative assay measured the equilibration of 
["C]mannitol  (molecular mass  =  186  D) across HUVEC 
as a measure of monolayer integrity. HUVEC were allowed 
to form a confluent monolayer overnight in the presence of 
either antisera or Fab fragments prepared from anti-CD31 
immune  sera  or  preimmune  control  serum.  There  was 
significantly greater equilibration of the ['4C]mannitol after 
a fixed 30-min time period in the presence of the anti-CD31 
antibodies, both as whole Ig and as Fab fragments, compared 
with preimmune controls  (Fig.  7  a).  However, when con- 
fluent preformed HUVEC monolayers were incubated with 
CD31 antisera overnight, no significant difference in mono- 
layer integrity could be detected, compared with preimmune 
controls (Fig.  7 b).  Preformed monolayers tested after 6 h 
incubation  with  antisera  gave  a  similar  result  (data  not 
shown). Antibodies and Fab fragments appear only to affect 
monolayer integrity when present during monolayer forma- 
tion and have no effects on HUVEC monolayer integrity once 
it is formed. 
Secondly, the integrity of the monolayers formed in the 
presence of preimmune and anti-CD31  Fab fragments was 
qualitatively assessed by electron microscopy (Fig. 8).  The 
monolayers formed in the presence of preimmune Fab frag- 
ments (Fig. 8 a) were uniform and the endothelial cells were 
in close contact and exhibited a flattened morphology on the 
filter surface with some ceils forming overlapping junctions 
with adjacent cells. These monolayers resembled previously 
published  studies  on  HUVEC  grown  on  such  permeable 
filters.  Both  immunofluorescent  and  immunoelectron  mi- 
croscopy confirmed that  CD31  was localized  to  cell-cell 
Fawcett  et  al.  Homotypic Binding by CD31  1237 Figure  7.  Effect of anti-CD31  antisera  and  Fab  fragments  on 
HUVEC monolayer permeability. (a) Typical paC]mannitol equili- 
bration results from HUVEC monolayers formed on Transwells in 
the presence of  CD31 and preimmune antisera or Fab fragments (50 
/~g/ml). Significant increases in monolayer permeability were ob- 
served when HUVEC were incubated with either CD31 antisera or 
Fab fragments during monolayer formation (P < 0.02). (b) Typical 
[t4C]mannitol  equilibration  results  from  preformed  HUVEC 
monolayers  incubated overnight with preimmune or CD31 antisera. 
No significant difference in equilibration values could be detected 
(P > 0.24). All monolayers were tested before the incubation and 
gave percentage equilibration values within the normal range (data 
not shown). 
junctions  (data  not  shown),  in  agreement  with  previous 
studies (Leach et al.,  1993; Ayalon et al.,  1994). 
Incubation of  anti-CD31 Fab fragments with HUVEC dur- 
ing monolayer formation had dramatic effects on endothelial 
cell  shape  and  monolayer integrity.  Several different cell 
morphologies were observed.  In  some  areas,  endothelial 
cells were elongated and they formed abnormally extended 
thin processes (Fig. 8 b, arrow). Other cells were not flat- 
tened and appeared raised from the surface of the filter (Fig. 
8 c). In other areas, cells formed disordered multilayer struc- 
tures rather than monolayers (Fig.  8 d).  Also,  there were 
small areas of filter devoid of cells. There was no evidence 
of any cytotoxic effects caused by anti-CD31 Fab fragments, 
since  there were  no  observable differences in  cell  ultra- 
structure between control and anti-CD31  treated HUVEC 
samples.  Thus,  anti-CD31  Fab  fragment incubation with 
HUVEC resulted in the formation of a disrupted structure 
rather than the normal cell monolayer. 
Discussion 
CD31 is a constitutively and abundantly expressed glycopro- 
tein on endothelial cells. Because of its highly localized ex- 
pression at sites of intercellular contacts, it has been sug- 
gested that CD31 may play a role in the maintenance of the 
integrity of  the endothelial monolayers lining the vasculature 
(Muller et al.,  1989; Bevilacqua, 1993). 
It has already been established that CD31  exhibits both 
homotypic and heterotypic adhesive properties. While the 
focus of this study has been to dissect the homotypic adhe- 
sion  mechanism,  it  should be  noted that  CD31  can  also 
mediate heterotypic adhesion (Muller et al., 1992). The bet- 
erotypic site has been mapped to domain 2, which contains 
a  consensus motif for the recognition of heparan sulphate 
(DeLisser et al., 1993). The homotypic binding mechanism 
has not yet been defined. 
To study the homotypic binding mechanism, the approach 
we have adopted relies on the presentation of recombinant 
chimeric forms of CD31-Fc to  CD31 + cell lines or COS 
cells expressing wild-type or truncated forms of CD31. We 
adopted this strategy for two reasons. First, it is possible to 
control for homotypic versus heterotypic pathways by use of 
mock transfectants, irrelevant chimeric proteins, and inclu- 
sion of heparin in the binding assays.  Secondly, the adhesion 
assays are quantitative and highly reproducible (Fawcett et 
al.,  1992; Simmons,  1993). 
Using a  combination of direct adhesion assays with chi- 
meric CD31-Fc deletion proteins and blocking assays with 
mAbs and the chimeric CD31-Fc deletion proteins, we found 
that the homotypic binding mechanism involves an extensive 
surface  over  multiple  domains.  Key  sites  are  contained 
within domains 2 and 3, as well as within domains 5 and 6. 
A model consistent with our data is that CD31 on one cell 
may interact with CD31 on another cell in an antiparaUel and 
fully interdigitating mode. Binding could involve a two-stage 
process of initial docking or alignment of the two molecules 
along their length, followed by specific engagement of bind- 
ing sites in domains 2 and 3, as well as domains 5 and 6. Al- 
though we have not shown which domains recognize D2 and 
D6, it is plausible that in an antiparallel interaction, D2-3 
bind to D5-6 and vice versa. 
A  similar mechanism has recently been proposed to ex- 
plain the mode of interaction of another homotypic adhesin 
carcinoembryonic antigen (CEA) (Zhou et al.,  1993). The 
extracellular domain of CEA consists of seven Ig domains, 
and by constructing CEA/NCAM chimeras and deletion mu- 
tants, the data was consistent with a model based on double 
reciprocal interactions between antiparallel CEA molecules 
aligned in trans. 
From the initial studies, mapping the binding sites in IgSF 
members, particularly the mutagenesis carried out on CD2 
(Peterson and  Seed,  1987) and CD4  (Peterson and Seed, 
1988), a model emerged which suggested that key residues 
located in single Ig domains were important for mediating 
binding. In addition, it seemed that the additional Ig domains 
merely acted as a stalk, projecting the dominant binding do- 
main  away  from  the  cell  membrane  above  the  cellular 
glycocalyx. There are many IgSF adhesion molecules where 
more than one domain in the molecule contributes to the 
binding site.  VCAM-1 has two binding sites, one in domain 
1 and one in domain 4,  for its ligand,  very late activation 
antigen-4 (VLA-4) (Osborn et al.,  1992). In this case, the 
domains seem to be able to work independently, but they 
have  different  properties.  Another  example  is  ICAM-1, 
which uses domain 1 to bind to one of its ligands, LFA-1, and 
uses domain 3 to bind to another leukocyte integrin, Mac-1 
(Staunton et  al.,  1990;  Diamond  et al.,  1991).  We have 
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ments disrupt HUVEC monolayer 
morphology.  Electron  micro- 
graphs  of  HUVEC  monolayers 
formed in the presence of either 
preimmune (A) or anti-CD31 Fab 
fragments at 50 ~g/ml (B-D). In 
B, the arrow indicates the abnor- 
mally  extended  cell  processes. 
Bar, 2 ~m. 
Fawcett et al. Homotypic Binding by CD31  1239 shown recently that ICAM-3, a very close relative of  ICAM-1, 
uses domains 1 and 2 to bind to LFA-1 (Holness et al., 1995). 
Thus, in the case of VCAM and ICAMs-1 and -3, a large sur- 
face encompassing many Ig domains is involved in ligand 
binding. 
From this recent work and our present study, a more com- 
plex picture is beginning to emerge, where several Ig do- 
mains in an adhesion molecule may actively contribute to en- 
gagement of ligand and not act merely as a passive stalk. 
In addition to the homotypic contact formation, CD31 can 
lead to the recruitment or amplification of/31, and to a lesser 
extent,/32 integrin-mediated adhesion (Tanaka et al., 1992; 
Piali et al., 1993). Using CD8+CD31 ÷ T cells, Tanaka et al. 
(1992) showed that cross-linking CD31  using single mAbs 
could upregulate/31 adhesion, and they postulated that one 
of the key roles of CD31  is to act as an adhesion amplifier. 
Thus, the primary role of CD31-CD31 contacts may not be 
to establish strong adhesion per se, but rather as elements 
in cell-cell recognition, to allow other adhesive paths to be 
recruited or upregulated.  We have shown that CD31(D1- 
D6)TM expressed in a heterologous cell (COS) can recruit 
or amplify/31 integrin adhesion. 133 integrins do not seem 
to be involved. Recruitment of/31 adhesion is not a general 
feature of  COS transfectants binding to chimeric Fc proteins; 
neither LFA-I+COS cells binding to ICAM-I(D1-D5)Fc  nor 
NCAM+COS cells binding to NCAM-Fc led to the recruit- 
ment of/31  integrin adhesion. Moreover, COS cells do not 
bind intrinsically to an irrelevant IgSF-Fc chimera (MUC18- 
Fc) even during 3 h. Establishment of direct CD31-CD31 
homotypic contacts for >130 rain and ~<60 rain is needed for 
/31 pathways to be amplified. After that homotypic contact 
period,  the/31  integrin pathway seems to be engaged and 
adhesion then occurs without the need for continued CD31- 
CD31  contacts. 
The molecular basis of this apparent cross-talk is not yet 
defined. The interaction between CD31 and/31 integrins may 
occur via direct intermolecular contacts or indirectly via an 
adaptor molecule or via intracellular signaling events. There 
are many other cases of cooperative interactions between 
adhesion molecules and other molecules in the same cell. 
For example, NCAM and L1 are thought to pair, probably 
via glycan/lectin interactions, to produce "assisted homo- 
philic binding" (Kadmon et al.,  1990),  i.e., cis association 
of NCAM-L1  yields increased L1-L1 adhesion (Horstkorte 
et al., 1993).  The integrin-associated protein IAP, which is 
a unique member of the IgSF comprising a single Ig domain 
attached  to  a  transmembrane  domain  of  five  spanning 
regions,  binds  to the  otv/33 integrin.  Anti-IAP mAbs  can 
modulate  otv/33 integrin  function  (Linberg  et  al.,  1993; 
Schwartz et al., 1993).  Embigin, an IgSF member contain- 
ing two Ig C2  domains, which is expressed early during 
mouse embryogenesis (Huang et al., 1993),  shows remark- 
ably similar properties to those found here for CD31. L cells 
expressing embigin adhered to BSA-coated  tissue culture 
plastic, whereas parental L cells did not. Anti-/31 antiserum 
and GRGDS peptide inhibited this adhesion. The ability of 
embigin-expressing L cells to adhere to BSA coated plastic 
in a  /31  integrin-dependent manner parallels our system, 
where CD31  expressing COS cells adhere to an identical 
surface. The ligand used by either of these cells has not been 
defined. Interestingly, embigin+L cells bind to fibronectin 
as efficiently as do the parental L cells, implying that the 
effect of  the IgSF//31 integrin interaction is evident only when 
the adhesion ligand is limiting. 
There is much circumstantial evidence implicating CD31 
in intercellular adhesion of endothelial cells. This evidence 
derives largely from observations that CD31  is often local- 
ized at sites of cell-cell contact. There is some experimental 
evidence that the bovine homologue of CD31, endoCAM, is 
involved in interendothelial cell adhesion, since polyclonal 
anti-endoCAM antibodies disrupt the formation of bovine 
adrenal  capillary endothelial monolayers (Albelda et al., 
1990).  However,  there have been no direct demonstrations 
or quantitative analyses of a role for human CD31 in the for- 
mation or maintenance of interendothelial contacts. 
To directly test the role of CD31 in human endothelial cell 
adhesion, we generated a polyclonal anti-CD31 antiserum 
that blocks the homotypic adhesion process. Anti-CD31 Fab 
fragments had dramatic effects on the formation of an inte- 
gral endothelial monolayer, judged both quantitatively by 
low molecular mass solute equilibration, and qualitatively 
by electron microscopy. The anti-CD31 reagents were only 
effective when  presented  to  the  endothelial cells  during 
monolayer formation, i.e,  during the time when interen- 
dothelial cell-cell contacts were forming. The antisera were 
completely without effect when presented to an already es- 
tablished monolayer, even though the endothelial cells in 
these layers were still expressing very high constitutive levels 
of CD31. 
There are two possible explanations for this difference. 
The anti-CD31  Fabs may be unable to compete with es- 
tablished CD31-CD31  contacts and break the monolayer 
once formed. Alternatively, CD31-CD31 interactions could 
mediate growth controlling signals to endothelial cells that 
are crucial during the process of monolayer formation, but 
become irrelevant once formed. We favor the latter model 
because the Fab fragments are clearly capable of inhibit- 
ing homotypic adhesion of CD31+COS  cells to CD31(D1- 
D6)Fc. Given this, the Fab fragments should be able to com- 
pete for binding to CD31 and disrupt monolayers if the main 
function of CD31  is to function as an adhesion molecule. 
The  role  of CD31  in  the  initial  formation of interen- 
dothelial contacts was also demonstrated by the effects of 
CD3 I(D1-D6)Fc chimera on endothelial cell growth. Prema- 
ture  presentation  of CD31(D1-D6)Fc  to  preconfluent en- 
dothelial monolayers caused significant inhibition of cell 
growth. It is possible that CD31-CD31  contacts play a key 
role in sensing the density of endothelial cells; as endothelial 
cells begin to contact each other, CD31-CD31  binding in 
trans  between two neighboring cells may deliver negative 
signals back into those cells, taking them out of the division 
cycle  and  thus  maintaining  a  quiescent  state  once  the 
monolayer has formed. 
Thus, current evidence suggests that CD31  may have at 
least two distinct functions: first as a cell-cell recognition 
molecule involved in the formation of initial intercellular 
contacts before handing over to other CAMs, and secondly, 
as a mediator of contact-dependent growth inhibition. 
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